EverHint Lens - Sarepta Therapeutics, Inc. ($SRPT) - Yahoo Finance Top Gainer (+28%) Stock Analysis - March 25, 2026

Analysis Date: 2026-03-25
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

Executive Summary

Sarepta Therapeutics, Inc. is currently trading at $22.67 (🟢 +28.71% today) with a market capitalization of $2.38B.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

Price & Valuation

Current Price: $22.67 (at 12:01 PM ET)
Current Volume: 9.7M
Day Range: $19.67 - $22.75
52-Week Range: $10.42 - $76.67
P/E Ratio: -3.32

DCF Valuation: Not applicable (negative intrinsic value)
DCF model (unlevered) calculated as of 2026-03-25.

Market Context

Healthcare Sector: 0.91928% | Sector P/E: 26.37

Major Indices:

• S&P 500: $6594.70 (🟢 +0.58%)
• NASDAQ Composite: $21940.42 (🟢 +0.82%)
• Dow Jones Industrial Average: $46419.25 (🟢 +0.64%)

Peer Comparison

Peer comparison (11 companies):

• SRPT - Sarepta Therapeutics, Inc. ($22.67, +28.7%, $2.38B) ← Current
• IBRX - ImmunityBio, Inc. ($8.20, +10.5%, $8.43B)
• COGT - Cogent Biosciences, Inc. ($36.89, +5.5%, $5.99B)
• DNLI - Denali Therapeutics Inc. ($21.46, +2.3%, $3.40B)
• BEAM - Beam Therapeutics Inc. ($24.22, +1.1%, $2.47B)
• ETNB - 89bio, Inc. ($14.84, 0.0%, $2.20B)
• ADPT - Adaptive Biotechnologies Corporation ($14.25, +2.5%, $2.19B)
• RCUS - Arcus Biosciences, Inc. ($21.48, +6.1%, $2.16B)
• AGIO - Agios Pharmaceuticals, Inc. ($29.63, +4.5%, $1.74B)
• MLYS - Mineralys Therapeutics, Inc. ($24.37, +6.5%, $1.62B)
• RXRX - Recursion Pharmaceuticals, Inc. ($3.15, -0.6%, $1.41B)

Financial Performance

Latest Quarter (2025-12-31):

• Revenue: $442.93M
• Net Income: $-282.85M
• EPS: $-2.74
• Revenue Growth (QoQ): +10.9%

Stock Split History

SRPT has executed 1 stock split(s) historically

• 2012-07-12: 1-for-6 split

Cumulative Split Factor: 0x (1 share in 1987 = 0 shares today)

Most recent split: 1-for-6 on 2012-07-12

Earnings Calendar

Next Earnings Report: 2026-05-05 (Before Market Open)

• EPS Estimate: $1.06
• Revenue Estimate: $0.48B

Most Recent Report: 2026-02-25

• EPS: $-3.58 (Est: $-1.20) ✗ Miss
• Revenue: $0.44B

Historical Data: 121 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

• Target: $24.50 (+8.1% upside)
• Range: $16.00 - $32.00
• Median: $23.50

Next Quarter Estimates (2027-12-31):

• Revenue: $409.27M
• EPS: $0.53

Analyst Consensus

Overall Rating: Buy

Rating Distribution (738 total ratings):

• 🟢 Buy/Outperform: 481 (65.2%)
• ⚪ Hold/Neutral: 155 (21.0%)
• 🔴 Sell/Underperform: 45 (6.1%)

Recent Analyst Actions:

• Wedbush (2025-12-09): Initiate Outperform
• BMO Capital (2025-09-22): Upgrade Market Perform → Outperform
• Barclays (2025-07-27): Downgrade Overweight → Underweight
• Deutsche Bank (2025-07-19): Downgrade None → Sell
• Needham (2025-07-18): Downgrade Buy → Hold

Consensus based on 738 analyst ratings from major financial institutions

Trading Signals

Our technical analysis identified 3 trading signal(s) in the last 60 days:

• 2026-03-09: Ema10 Price Macd - EMA10_Price_MACD_Buy @ $17.64
• 2026-02-05: Sma20 Sma50 - SMA20_x_SMA50_Sell @ $17.03
• 2026-01-30: Ema10 Ema30 - EMA10_x_EMA30_Sell @ $20.34

Insider Activity

Recent Transactions (Last 10):

• Buys: 0
• Sells: 10

Notable Transactions:

• 2026-03-11: Estepan Ian Michael - Sell (Tax Withholding, 1,097 shares @ $17.03)
• 2026-03-11: Wong Ryan Ho-Yan - Sell (Tax Withholding, 256 shares @ $17.03)
• 2026-03-11: Rodino-Klapac Louise - Sell (Tax Withholding, 948 shares @ $17.03)

Congressional Trading Activity

Tracking recent stock transactions by U.S. Congress members

House of Representatives: 10 transactions tracked

Recent Activity:

• 🟢 Josh Gottheimer (NJ05): Purchase on 2023-07-14 @ $107.84, Amount: $1,001 - $15,000
• 🔴 Josh Gottheimer (NJ05): Sale on 2023-06-13 @ $129.85, Amount: $1,001 - $15,000
• 🔴 Daniel Goldman (NY10): Sale on 2023-04-10 @ $140.38, Amount: $15,001 - $50,000
• 🟢 Josh Gottheimer (NJ05): Purchase on 2023-03-06 @ $155.99, Amount: $1,001 - $15,000
• 🟢 Daniel Goldman (NY10): Purchase on 2023-03-06 @ $155.99, Amount: $15,001 - $50,000

Congressional trading data sourced from official disclosure filings

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

Recent headlines dominate with highly positive news on Sarepta Therapeutics' promising early clinical results from siRNA therapies targeting FSHD1 and DM1, driving a 20-26% stock surge. Earlier reports include regulatory updates for full FDA approvals and study enrollments, offsetting prior negatives like a Q4 earnings miss and CEO retirement. Overall sentiment reflects strong optimism for the company's rare disease pipeline.

Key Themes:

• Promising siRNA Clinical Data
• Stock Price Surge
• Pipeline and Regulatory Progress

Sentiment: Positive (92% confidence)

Reddit Sentiment

Community Discussion (last 30 days from r/wallstreetbets, r/stocks, r/investing):

Overall Sentiment: Strongly Bearish 📉📉 (Score: -0.563)

Post Analysis:

• Total posts: 2
• Bullish: 0 (0.0%)
• Bearish: 2 (100.0%)
• Neutral: 0 (0.0%)
• Total engagement: 4 (upvotes + comments)

Note: Sentiment score ranges from -1.0 (very bearish) to +1.0 (very bullish), weighted by post engagement.

Recent News

5 most recent articles covering SRPT:

• Sarepta Therapeutics' experimental siRNA therapies show promising early results (proactiveinvestors.com, 2026-03-25) — Read more
• Why Is Sarepta Therapeutics Stock Exploding Today? (benzinga.com, 2026-03-25) — Read more
• The VIX Crashes Out, For Now, on Hope For Peace and Cheaper Oil (247wallst.com, 2026-03-25) — Read more
• Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout? (247wallst.com, 2026-03-25) — Read more
• Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 (businesswire.com, 2026-03-25) — Read more

Full news analysis based on 30 recent articles

Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-03-25 09:01:46 AM PDT

Disclaimer: This is not investment advice. Always do your own research before making investment decisions.